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1.91; p=0.04).
Conclusion: Depression is associated with all-cause mortality and cardiovascular death
or hospitalization following acute MI complicated by heart failure. Studies are warranted
to evaluate whether a depression intervention can improve survival and/or reduce hospi-
talization for these patients.
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BACKGROUND
Randomized clinical trial (RCT) have shown that ACE-inhibitors (ACE-I) and β-blockers
(βB) improve survival in patients with heart failure (HF) with additive effect. Whether
these therapeutic benefits are maintained in HF patients of the “real word” is debated.
This study compared survival of HF patients from the general population as a function of
cardiovascular (CV) drug use.
METHODS
All hospital admissions, drug prescriptions (National Health Service Drug Prescription
Database), and mortality data of the entire population (approximately 360,000) residing
in the health district of Ravenna, Italy have been recorded since 1996. Patients dis-
charged from hospital with a first diagnosis of HF (ICD 9 code 428) from 01.01.1997 to
12.31.1999 were selected from this database and followed up for one year. Patients were
grouped into 5 cohorts according to drug prescription during the follow-up: diuretics (D)
alone, ACE-I alone, D+ACE-I, D+ACE-I+βB, and other drugs. Mortality rates were com-
puted using a person-years denominator. Cox’s model was used to compute mortality
hazard ratio (HR) and 95% confidence interval (95% CI), adjusting for age, sex, history
of: diabetes, hypertension, heart disease and previous CV events (myocardial infarction,
coronary artery disease, stroke, and transient ischemic attack).
RESULTS
2,441 HF patients (mean age 78 ± 10 years; females 53.7%) were included. Of them,
20.2% were on D, 7.2% on ACE-I, 56.2% on D+ACE-I, 5.4% on D+ACE-I+βB, and 11.0%
on other drugs. Crude cumulative mortality was 36.8%, 26.7%, 20.8%, 3.9% and 34.1
respectively (p<0.001). Compared to patients receiving D+ACE-I+βB, the risk of death
increased significantly in those on other regimens, with adjusted HRs (95% CIs) of 3.9
(1.6-9.4), 5.5 (2.2-14.0), 6.3 (2.6-15.6), 6.5 (2.6-16.1) in those on D+ACE-I, ACE-I, D or
other drugs, respectively.
CONCLUSION
In this large cohort of HF patients from the general population, a therapeutic regimen
based on the association D+ACE–I+βB was associated with the lowest mortality. Survival
decreased progressively in participants on D+ACE-I, ACE-I, D, and other drugs. These
results from a non-experimental setting strongly support those obtained from RCT.
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Background: While the incidence and causes of death in heart failure (HF) patients with
reduced left ventricular (LV) systolic function have been previously reported, these have
not been described in patients with preserved systolic function. Methods: The Cande-
sartan in Heart Failure (CHARM) trial enrolled 7601 patients with symptomatic heart fail-
ure, and EF ranging from 5% to 91%. Cause of death was classified by an independent
review committee. The annualized incidence of death was calculated in each quintile
(median follow-up 38 mos). Results: All-cause and CV death declined with each increas-
ing quintile of ejection fraction, whereas non-CV death was similar across quintiles. The
proportion of non-CV death increased in the highest quintile of EF. Sudden death and
fatal HF accounted for the majority of CV death and the proportion of death attributable to
sudden death or HF decreased with EF. The annual incidence of fatal MI was low (<1% in
all groups). The proportion of deaths attributable to MI or stroke was similar across quin-
tiles. Conclusion: In HF patients with a broad range of ejection fractions, death attrib-
uted to sudden death and HF accounted for the majority of the cardiovascular death,
although in decreasing absolute number and proportion with increasing EF. These find-
ings have important implications for the choice of end-points in trials in patients with heart
failure and preserved LV systolic function. 
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Background: There is a paucity of information on renal insufficiency (RI) in patients (pts)
with heart failure (HF) due to exclusion of RI pts from HF clinical trials. Methods: Data
from 46,599 hospitalizations (Apr, 2003) for decompensated HF were collected in the
ADHERETM Registry. Of 35,423 pts with Cr < 2.0 mg/dl, 10,648 (30%) did not receive
chronic diuretics (ChD) (A) and 24,775 (70%) did (B). Of 10,317 pts with Cr > 2.0 mg/dl,
2,937 (28%) did not receive ChD (C) and 7,380 (72%) did (D). Resource utilization and
outcomes were compared in the 4 groups (Chi square and ANOVA). Results: There was
a stepwise increase in in-hospital mortality with the lowest rate occurring in A and the
highest in D. In pts with low and high Cr, use of ChD was associated with the highest
mortality rate. A stepwise decrease in the percentage of cases who were completely
asymptomatic at discharge, with the highest percentage in A and the lowest percentage
in D, was observed. Use of ChD was associated with fewer asymptomatic discharges in
pts with low and high Cr, (46% vs. 52% and 39% vs. 45%; both P < 0.0001). There was a
stepwise increase in hospital length of stay (LOS) with the shortest in A and the longest
in D. In pts with low and high Cr ChD were associated with longer LOS (5.5 ± 4.9 vs. 5.8
± 6.1 days, P<0.0001 and 6.1± 5.8 vs. 6.9 ± 6.1 days, P< 0.0001). Conclusions: RI
worsens patient outcomes in terms of resource utilization, symptom status and survival.
ChD were associated with poorer outcomes and greater resource utilization in pts with
and without RI.
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Introduction: Renal dysfunction frequently accompanies heart failure progression, and
deterioration of renal function in patients (pts) admitted with decompensated CHF is
common. However, the prognostic significance of worsening renal function in this setting
is not known.
Methods: We studied the relation between deterioration of renal function and 6-month
mortality in 498 pts admitted with decompensated CHF. Deterioration of renal function
was defined as an increase of > 0.5 mg/dL in creatinine level within 14 days from admis-
sion.
Results: At 14-days, 103 pts (21%) had evidence of deteriorating renal function. During
a 6-month follow-up, 112 pts (22%) died. Kaplan-Meier analysis is shown in the Figure. A
Cox proportional-hazards model, adjusted for age, gender, diabetes, etiology of CHF,
baseline creatinine, baseline heart rate, EF, atrial fibrillation, and medications (ACE inhib-
itors, β-blockers, digoxin, or amiodarone use), showed that deteriorating renal function
was a strong independent predictor of 6-month mortality (RR = 2.93, 95% CI 1.81-4.72, p
< 0.0001). Baseline creatinine was also an independent predictor of 6-month mortality
(RR = 1.20 for every 1.0 mg/dL increase, 95% CI 1.06-1.36, p = 0.003), but was not pre-
dictive of deteriorating renal function.
Conclusion: In pts admitted for heart failure decompensation, evidence of deteriorating
renal function is a powerful independent predictor of short-term mortality. 
